Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
3.230
+0.110 (3.53%)
At close: Mar 6, 2026, 4:00 PM EST
3.280
+0.050 (1.55%)
After-hours: Mar 6, 2026, 7:17 PM EST
Prelude Therapeutics Employees
Prelude Therapeutics had 131 employees as of December 31, 2024. The number of employees increased by 3 or 2.34% compared to the previous year.
Employees
131
Change (1Y)
3
Growth (1Y)
2.34%
Revenue / Employee
$80,153
Profits / Employee
-$853,221
Market Cap
266.14M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 131 | 3 | 2.34% |
| Dec 31, 2023 | 128 | 6 | 4.92% |
| Dec 31, 2022 | 122 | 6 | 5.17% |
| Dec 31, 2021 | 116 | 48 | 70.59% |
| Dec 31, 2020 | 68 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Humacyte | 220 |
| Protalix BioTherapeutics | 213 |
| Voyager Therapeutics | 172 |
| Cibus | 159 |
| MediWound | 111 |
| Alector | 103 |
| Sol-Gel Technologies | 34 |
| Achieve Life Sciences | 25 |
PRLD News
- 4 weeks ago - Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor - GlobeNewsWire
- 3 months ago - Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs - GlobeNewsWire
- 3 months ago - PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 4 months ago - Prelude Therapeutics Incorporated (PRLD) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm - Business Wire
- 4 months ago - Prelude Therapeutics Announces Strategic Business Update - GlobeNewsWire
- 4 months ago - Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors - GlobeNewsWire